Clinical comparison of radiolocalization of two monoclonal antibodies (mAbs) against the TAG-72 antigen

Nucl Med Biol. 1994 Jan;21(1):9-15. doi: 10.1016/0969-8051(94)90124-4.

Abstract

Ten patients with colorectal cancer metastases received 125I-B72.3 and 131I-CC49 prior to laparotomy (five patients received 1 mg, and five 20 mg of each mAb). Tumor:serum ratios of 131I-CC49 were better than those of 125I-B72.3 (P < 0.01 at 1 mg; P = 0.05 at 20 mg; P < 0.01 at both doses). All known lesions > or = 1 cm in diameter were visualized at the 20 mg dose. There was no difference in absolute tumor uptake of 125I-B72.3 or 131I-CC49. We conclude that mAb CC49 has better relative uptake in colorectal cancers than mAb B72.3.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adrenal Gland Neoplasms / diagnostic imaging
  • Adrenal Gland Neoplasms / secondary
  • Adult
  • Aged
  • Antibodies, Monoclonal / pharmacokinetics
  • Antibodies, Monoclonal / therapeutic use*
  • Antigens, Neoplasm / immunology*
  • Colorectal Neoplasms / diagnostic imaging
  • Colorectal Neoplasms / pathology
  • Colorectal Neoplasms / radiotherapy*
  • Female
  • Glycoproteins / immunology*
  • Humans
  • Immunoconjugates / pharmacokinetics
  • Immunoconjugates / therapeutic use*
  • Iodine Radioisotopes / pharmacokinetics
  • Iodine Radioisotopes / therapeutic use*
  • Liver Neoplasms / diagnostic imaging
  • Liver Neoplasms / secondary
  • Male
  • Middle Aged
  • Pelvic Neoplasms / diagnostic imaging
  • Pelvic Neoplasms / secondary
  • Radioimmunotherapy
  • Recurrence
  • Tomography, Emission-Computed, Single-Photon

Substances

  • Antibodies, Monoclonal
  • Antigens, Neoplasm
  • Glycoproteins
  • Immunoconjugates
  • Iodine Radioisotopes
  • tumor-associated antigen 72